Actively Recruiting
Observational Study of Premium-PANAF Antivenom Safety and Effectiveness in Treating Snakebite Envenomation in Ethiopia
Led by Medecins Sans Frontieres, Netherlands · Updated on 2026-06-22
600
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Snakebite envenomation is a serious neglected tropical disease with high death rates in Sub-Saharan Africa. Current treatments require cold storage and have supply challenges, affecting patient outcomes in resource-limited areas. The World Health Organization recommended the use of Premium-PANAF, a lyophilised polyvalent snake antivenom that does not need cold-chain storage, and Mdecins Sans Frontires updated its protocol to make it the standard treatment at a health center in Ethiopia starting June 2025. This observational study will follow up to 600 patients treated with Premium-PANAF antivenom as part of routine care to collect real-world data on its safety and effectiveness in Ethiopia. Patients admitted with snakebite envenomation will be observed after receiving the antivenom, with no experimental treatments given. The study aims to provide evidence to guide national and global treatment recommendations. Participants will be monitored for allergic reactions and correction of blood clotting problems within 6 hours after treatment. Additional outcomes include bleeding control, mortality, need for rescue treatments, surgical interventions, and other safety measures tracked up to 42 days after treatment. Data collection will help assess how well Premium-PANAF works and its safety profile in a real-world setting over the study period ending in 2026.
CONDITIONS
Brief Title
Polyvalent Antivenom (Premium-PANAF) for Snakebite Envenoming in Ethiopia
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here